Selecting Frontline Therapy for KRAS+ mutated lung adenocarcinoma
Cinical trial data and guidelines on optimal first-line regimens for metastatic KRAS mutated lung adenocarcinoma.
EP: 1.An overview on KRAS+ mutated lung adenocarcinoma
EP: 2.Selecting Frontline Therapy for KRAS+ mutated lung adenocarcinoma
EP: 3.KRYSTAL-1: Review of Key Efficacy Data
EP: 4.Comparing the Efficacy and Safety of KRAS G12C inhibitors for patients with NSCLC
EP: 5.Strategies for monitoring and mitigating hepatotoxicity with KRAS G12C inhibitors
EP: 6.Key Considerations for Treating patients with NSCLC using KRAS inhibitors
Case: A 64-year-old male diagnosed with a KRAS G12C mutated stage IV adenocarcinoma
Clinical Presentation:
- A 64-year-old male presents with cough and fatigue
- PMH: hyperlipidemia (well controlled with simvastatin), GERD (takes Omeprazole)
- SH: married with 2 grown children who live in other states; 30 pack-year smoking history; no family history of cancer.
Initial Clinical Workup and Diagnosis:
- CT chest showed right upper lobe lung mass with contralateral lung nodules concerning metastases.
- PET/CT revealed additional metastases in the liver.
- Molecular Testing: KRAS G12C mutation
- Staging: IV adenocarcinoma; ECOG PS 1
Initial Treatments:
- Patient was initiated on carboplatin-pemetrexed + pembrolizumab.
- Good initial response after 4 cycles but progressed after 8 months.
Disease Progression and Subsequent Treatments:
- Experienced disease progression after 8 months of carboplatin-pemetrexed + pembrolizumab, notably growth in hepatic metastases
- Confirmed progression on CT and PET/CT scans
- After progression on initial chemo+IO, molecular testing confirmed retained KRAS G12C mutation.
- The patient then started on second-line therapy with the adagrasib.
Phase 3 CheckMate -73L of Nivolumab/Ipilimumab in NSCLC Misses PFS End Point
May 13th 2024Nivolumab with ipilimumab did not lead to progression-free survival benefits in patients with unresectable stage III non-small cell lung cancer, missing the primary end point of the CheckMate -73L study.
Read More
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More
